Eucommia (Eucommia ulmoides)

Eucommia ulmoides is a traditional Chinese medicinal bark containing chlorogenic acid and geniposidic acid that supports cardiovascular health through ACE inhibition and nitric oxide enhancement. Clinical studies demonstrate its ability to reduce blood pressure by approximately 7.5/3.9 mmHg in hypertensive patients.

Origin & History

Eucommia ulmoides, also known as Duzhong or Tochu, is a deciduous tree native to China from temperate regions, cultivated for its bark, leaves, and seeds in traditional East Asian medicine. Extracts are typically prepared via aqueous or ethanolic methods from bark or leaves, yielding polyphenolic compounds classified as lignans, iridoids, and phenolics.

Historical & Cultural Context

Eucommia ulmoides (Duzhong) has been used in Traditional Chinese Medicine for over 2,000 years, documented in ancient texts like Shennong Bencao Jing, primarily for strengthening bones and tendons, tonifying kidney and liver yin, and treating hypertension. It is also integral to Japanese Kampo medicine as Tochu, where leaves and bark are prepared as tea for similar health applications.

Health Benefits

• Blood pressure reduction: Clinical trial showed 7.5/3.9 mmHg reduction in systolic/diastolic pressure (moderate evidence, PMID: 22214253)
• Chronic kidney disease support: Small trial (n=17) demonstrated significant blood pressure reduction in CKD patients (preliminary evidence, PMID: 40575587)
• Potential osteoarthritis relief: Two ongoing RCTs investigating pain reduction (evidence pending, NCT03744611)
• Stroke recovery: Animal studies show neuroprotective effects through gut microbiota modulation (preliminary evidence, PMID: 41288788)
• Bone health: Meta-analysis of 18 rat studies suggests osteoporosis benefits (animal evidence only)

How It Works

Eucommia's chlorogenic acid and geniposidic acid inhibit angiotensin-converting enzyme (ACE), reducing vasoconstriction and aldosterone release. The bark's lignans and iridoids enhance endothelial nitric oxide synthase activity, promoting vasodilation. Additional compounds like aucubin modulate calcium channels and support renal function through anti-inflammatory pathways.

Scientific Research

Human clinical evidence is limited to small-scale studies, with a randomized placebo-controlled trial (PMID: 22214253) showing blood pressure reduction using standardized bark extract (8% pinoresinol di-beta-D-glucoside). An exploratory trial (PMID: 40575587) in 17 participants found significant blood pressure improvements, particularly in those with mild chronic kidney disease. Two multicenter RCTs for osteoarthritis are underway but results are pending (NCT03744611, PMID: 31852118).

Clinical Summary

A randomized controlled trial demonstrated Eucommia extract reduced systolic blood pressure by 7.5 mmHg and diastolic by 3.9 mmHg in hypertensive patients over 8 weeks. A smaller preliminary study in 17 chronic kidney disease patients showed significant blood pressure improvements with daily supplementation. Current evidence is moderate quality with limited large-scale trials. Most studies used standardized bark extracts containing 3-5% chlorogenic acid at doses of 500-1000mg daily.

Nutritional Profile

Eucommia ulmoides bark (Du Zhong) is not consumed as a food source for macronutrients but contains a well-characterized array of bioactive compounds. Macronutrient content is negligible in typical therapeutic doses (3–15g dried bark). Key bioactive constituents include: (1) Lignans — pinoresinol diglucoside (0.1–0.5% dry weight), medioresinol, syringaresinol, identified as primary antihypertensive agents; (2) Iridoids — aucubin (~0.07–0.12% dry weight) and geniposide, contributing to anti-inflammatory and renal-protective effects; (3) Chlorogenic acid — a hydroxycinnamic acid derivative present at approximately 0.5–1.2% dry weight, contributing antioxidant and vasodilatory activity; (4) Gutta-percha (trans-polyisoprene) — a unique rubber-like polymer comprising 6–10% of bark dry weight, biologically inert but structurally distinctive; (5) Flavonoids — quercetin and rutin detected at trace levels (<0.05% dry weight); (6) Phenylpropanoids — including coniferin and syringin; (7) Minerals — bark contains modest calcium (~180–220 mg/100g dry weight), potassium (~300–400 mg/100g dry weight), magnesium (~50–80 mg/100g dry weight), and trace zinc and iron; (8) Dietary fiber — approximately 20–30% of dry bark weight as structural polysaccharides, though not consumed in fiber-relevant quantities in herbal doses. Bioavailability notes: Pinoresinol diglucoside requires gut microbiome conversion to aglycone forms for absorption; chlorogenic acid has moderate oral bioavailability (~30%); iridoid glycosides show variable absorption dependent on gut flora; standardized extracts (often to 1% pinoresinol diglucoside or 5% total iridoids) are used in clinical preparations to ensure consistent dosing.

Preparation & Dosage

Clinically studied dosages include: Bark extract standardized to 8% pinoresinol di-beta-D-glucoside at 500 mg three times daily (1.5 g/day) for hypertension; Leaf extract tablets for approximately 33 days in kidney disease studies (exact dose unspecified). Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Hawthorn, Hibiscus, Magnesium, Coenzyme Q10, Omega-3

Safety & Interactions

Eucommia is generally well-tolerated with mild gastrointestinal upset reported in some users. It may enhance the effects of ACE inhibitors and blood pressure medications, requiring medical supervision. The herb should be avoided during pregnancy due to insufficient safety data. No significant drug interactions have been documented, though caution is advised with anticoagulant medications.